The expression of tissue factor (TF) by cancer cells as well as the formation of procoagulant microparticles derived from activated platelets, are pivotal events leading to enhanced thrombin generation in patients with cancer (reviewed in [17–20]). The gene discussed is F3; the disease is cancer.